

Behavioral Health HEDIS® Measures Tip Sheet

CY 2019/HEDIS 2020

Measure	Ages	What is Needed to Close Care Gap	Timeframe
Follow-Up Care for Children Prescribed ADHD Medication, Initiation Phase (ADD)	Ages 6-12 years of age as of the newly prescribed prescription start date (Index Prescription Start Date)	Has one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase. Follow-up visit may be an outpatient, intensive outpatient, or partial hospitalization visit.	March 1, 2018 through February 28, 2019 Follow-up visit must occur 30 days following the Index Prescription Start Date
Follow-Up Care for Children Prescribed ADHD Medication, Continuation and Maintenance Phase (ADD)	Ages 6-12 years of age as of the newly prescribed prescription start date (Index Prescription Start Date)	Remains on medication at least 210 days and has two follow-up visits with practitioner with prescribing authority during the 270-day period (nine months) after the Initiation Phase ended (total of 300 days after the Index Prescription Start Date). Follow-up visit may be an outpatient, intensive outpatient, partial hospitalization visit, or telehealth visit.	March 1, 2018 through February 28, 2019 Follow-up visits must occur 300 days following the Index Prescription Start Date
Antidepressant Management, Acute Phase (AMM)	Ages 18 years and older as of April 30, 2019	Is treated with antidepressant medication, has a diagnosis of major depression, and remains on an antidepressant medication treatment for at least 84 days (12 weeks).	Initial dispense date May 1, 2018 through April 30, 2019 (Treatment can continue through December 31, 2019)
Antidepressant Management, Continuation Phase (AMM)	Ages 18 years and older as of April 30, 2019	Is treated with antidepressant medication, has a diagnosis of major depression, and remains on an antidepressant medication treatment for at least 180 days (six months).	Initial dispense date May 1, 2018 through April 30, 2019 (Treatment can continue through December 31, 2019)
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Ages 1-17 years as of December 31, 2019	Completes both of the following: <ul style="list-style-type: none"> • Blood glucose test or Hgb A1c test • LDL-C test or Cholesterol test 	January 1 through December 31, 2019

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Ages 1-17 years as of December 31, 2019	Has documentation of psychosocial care (psychotherapy, behavioral therapy, social work services, etc.) as first-line treatment in addition to a new prescription for an antipsychotic medication.	January 1 through December 31, 2019 (Prescription start dates are January 1 through December 1, 2019; first line treatment can occur up through December 31, 2019)
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	Ages 13 years and older as of the date of emergency department (ED) visit	ED visits for members with a principal diagnosis of alcohol or other drug abuse dependence (AOD), who has a follow-up visit for AOD with any practitioner. Two rates are reported: 1. The percentage of ED visits for which the member received follow-up within seven days of the ED visit (eight total days) with any practitioner, with a principal diagnosis of AOD. 2. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days) with any practitioner, with a principal diagnosis of AOD.	ED visits January 1 through December 1, 2019
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) *New measure for HEDIS 2020	Ages 13 years and older as of the date of discharge, stay, or event	Acute inpatient hospitalizations, residential treatment or detoxification visits for a diagnosis of substance use disorder among members 13 years of age and older that result in a follow-up visit or service for substance use disorder. Two rates are reported: 1. The percentage of visits or discharges for which the member receives follow-up for substance use disorder within the 30 days after the visit or discharge. 2. The percentage of visits or discharges for which the member receives follow-up for substance use disorder within the seven days after the visit or discharge.	Event occurring on or between January 1 and December 1, 2019
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Ages six years and older as of the date of ED visit	ED visits for members with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for	ED visits January 1 through December 1, 2019

		<p>mental illness with any practitioner.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. The percentage of ED visits for which the member receives follow-up within seven days of the ED visit (eight total days) with any practitioner, with a principal diagnosis of mental illness. 2. The percentage of ED visits for which the member receives follow-up within 30 days of the ED visit (31 total days) with any practitioner, with a principal diagnosis of mental illness. 	
Follow Up Visit After Hospital Stay for Mental Illness, Seven Day (FUH)	Ages six years and older as of the date of discharge	Has hospitalization for treatment of selected mental illness or intentional self-harm diagnoses and has a follow-up visit with a mental health practitioner within seven days of discharge.	Discharges January 1 through December 1, 2019
Follow Up Visit after Hospital Stay for Mental Illness, 30 Day (FUH)	Ages six years and older as of the date of discharge	Has hospitalization for treatment of selected mental illness or intentional self-harm diagnoses and has a follow-up visit with a mental health practitioner within 30 days of discharge.	Discharges January 1 through December 1, 2019
Initiation and Engagement of Alcohol or Other Drug Treatment, Initiation (IET)	Ages 13 years and older as of December 31, 2019	Treatment is initiated through an inpatient alcohol or other drug abuse (AOD) admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth, or medication treatment within 14 days of the diagnosis.	<p>New episodes of AOD abuse: January 1 – November 13, 2019</p> <p>(Services can be from January 1 – December 31, 2019)</p>
Initiation and Engagement of Alcohol or Other Drug Treatment, Engagement (IET)	Ages 13 years and older as of December 31, 2019	Treatment is initiated and has two or more additional alcohol or other drug abuse (AOD) services or medication treatment within 34 days of the initiation visit.	<p>New episodes of AOD abuse: January 1 through November 13, 2019</p> <p>(Services can be from January 1 through December 31, 2019)</p>
<p>Pharmacotherapy for Opioid Use Disorder (POD)</p> <p>*New measure for HEDIS 2020</p>	Ages 16 years and older as of December 31, 2019	Are diagnosed with an opioid use disorder (OUD) who have new OUD pharmacotherapy events with OUD pharmacotherapy for 180 or more days without a gap in treatment of eight or more consecutive days.	New event of OUD pharmacotherapy: July 1, 2018 through June 30, 2019

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Ages 19–64 as of December 31, 2019	Are diagnosed with schizophrenia or schizoaffective disorder and are dispensed and remain on an antipsychotic medication for at least 80% of their treatment period.	Index Prescription Start Date through December 31, 2019 (Index Prescription Start Date = earliest prescription dispensing date for any antipsychotic during CY 2019)
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	Ages 18–64 as of December 31, 2019	Completes LDL-C test	January 1 through December 31, 2019
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	Ages 18–64 as of December 31, 2019	Completes both of the following: <ul style="list-style-type: none"> • Hgb A1c test • LDL-C test 	January 1 through December 31, 2019
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Ages 18–64 as of December 31, 2019	Completes blood glucose test or Hgb A1c test (only one required)	January 1 through December 31, 2019

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).